Northern Trust Increased Stake in Cidara Therapeutics

Summary

North Trust increased its holdings in Celldex Therapeutics (NASDAQ: CLDX) by 6.2% during the fourth quarter of 2023, now holding 597,605 shares valued at $15.1 million. Analysts set an average target price for CLDX at $53.90. The stock opened at $20.10, with a 52-week range of $14.40 to $47.00. Celldex reported a quarterly loss per share of $0.81, below expectations, and revenue of $700,000, also below expectations.Market Beat

Impact Analysis

This event is primarily at the company level, focusing on Celldex Therapeutics. North Trust’s increased investment suggests confidence in Celldex’s long-term potential despite recent earnings misses and revenue shortfall. The company’s cash reserves of $673.3 million provide a financial buffer to support operations through 2027, potentially mitigating short-term losses.Reuters The adjustment in Morgan Stanley’s target price for Celldex reflects a cautious but optimistic outlook, emphasizing potential growth opportunities albeit with moderated expectations due to performance metrics.Stock Star While Celldex’s stock price is significantly below the target price, this could present a buying opportunity for risk-tolerant investors. However, given the reported losses, investors should weigh the risk of further underperformance against the company’s strategic plans and financial health.